Biomarin Pharmaceutical (NAS:BMRN) Cash From Discontinued Investing Activities

: $0 Mil (TTM As of Mar. 2023)

View and export this data going back to 1999. Start your Free Trial

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Biomarin Pharmaceutical's cash from discontinued investing activities for the three months ended in Mar. 2023 was $0 Mil. It means Biomarin Pharmaceutical received $0 Mil from discontinued investing activities. Biomarin Pharmaceutical's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Mar. 2023 was $0 Mil.

Biomarin Pharmaceutical Cash From Discontinued Investing Activities Historical Data

The historical data trend for Biomarin Pharmaceutical's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash From Discontinued Investing Activities

Biomarin Pharmaceutical Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash From Discontinued Investing Activities																-	-	-	-	-

Biomarin Pharmaceutical Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Biomarin Pharmaceutical Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (NAS:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Cash From Discontinued Investing Activities

Comparable Companies

Traded in Other Exchanges

BMRN:Mexico BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

Executives

Erin Burkhart	officer: GVP, Chief Accounting Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Andrea Acosta	officer: GVP, Chief Accouning Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST, SAN RAFAEL CA 94901
Charles Greg Guyer	officer: EVP, Chief Technical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Robert J. Hombach	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Willard H Dere	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Dennis Slamon	director	770 LINDARO STREET, SAN RAFAEL CA 94901
Jeffrey Robert Ajer	officer: SVP, Chief Commercial Of	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Daniel K Spiegelman	officer: EVP, Chief Financial Officer	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Brian Mueller	officer: VP, Corporate Controller	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Kenneth Bate	director	C/O MILLENNIUM PHARMACEUTICALS INC, 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139